Ignite Creation Date:
2024-05-06 @ 2:03 AM
Last Modification Date:
2024-10-26 @ 11:13 AM
Study NCT ID:
NCT01957527
Status:
COMPLETED
Last Update Posted:
2015-08-20
First Post:
2013-09-30
Brief Title:
Offset of Ticagrelors Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry EndoPAT Assay
Sponsor:
University of Patras
Organization:
University of Patras
Study Overview
Official Title:
Offset of Ticagrelors Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry EndoPAT Assay
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ticagrelor administration whose molecule resembles to adenosine led to reduction in overall mortality and thrombotic cardiovascular CV events when directly compared to clopidogrel in the PLATO trial implicating possible pleiotropic actions for the drug It has been shown that ticagrelor increases adenosine concentration by interfering with its red blood cells uptake and by inducing the release of ATP which is then converted to adenosine Recent studies in healthy volunteers and patients with coronary artery disease CAD have shown that ticagrelor increases the coronary blood flow in response to intravenous adenosine administration Ticagrelor administration in comparison with other P2Y12 inhibitors may influence the endothelial function as assessed by the Peripheral Arterial Tonometry method EndoPAT 2000 system Itamar Medical Caesarea Israel which is a method for evaluating endothelial dysfunction and has been found to positively correlate with flow mediated dilatation FMD
This is a prospective observational study which will be conducted in patients with coronary artery disease subjected to percutaneous coronary intervention PCI under ticagrelor maintenance dose MD 90mg x 2 who are about to stop treatment due to completion of 1 year antiplatelet therapy Eligible patients will be subjected to peripheral arterial tonometry at Day 0 immediately after receiving the last pill of ticagrelor and at day 2 and day 5 post study drug discontinuation Peripheral blood sample will be taken from the patients at Day 0 for genotype analysis
This is a prospective observational study which will be conducted in patients with coronary artery disease subjected to percutaneous coronary intervention PCI under ticagrelor maintenance dose MD 90mg x 2 who are about to stop treatment due to completion of 1 year antiplatelet therapy Eligible patients will be subjected to peripheral arterial tonometry at Day 0 immediately after receiving the last pill of ticagrelor and at day 2 and day 5 post study drug discontinuation Peripheral blood sample will be taken from the patients at Day 0 for genotype analysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None